Abstract
As a multi-system disease, chronic heart failure requires a complex, multimodal therapy. Achieving maximum guideline adherence in (advanced) chronic heart failure can therefore become a challenge. The important decrease in morbidity and mortality seen lately largely depends on consequent and sometime tedious implementation of guideline targets. The present paper provides a comprehensive overview on medical therapeutic strategies with a particular focus of onset and discontinuation of drugs in patients with chronic systolic dysfunction.
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / administration & dosage
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Cardiac Glycosides / administration & dosage
-
Cardiac Glycosides / adverse effects
-
Cardiotonic Agents / administration & dosage*
-
Cardiotonic Agents / adverse effects
-
Chronic Disease
-
Diuretics / administration & dosage
-
Diuretics / adverse effects
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Interactions
-
Drug Therapy, Combination
-
Heart Failure / drug therapy*
-
Humans
-
Mineralocorticoid Receptor Antagonists / administration & dosage
-
Mineralocorticoid Receptor Antagonists / adverse effects
-
Systole / drug effects
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Cardiac Glycosides
-
Cardiotonic Agents
-
Diuretics
-
Mineralocorticoid Receptor Antagonists